Literature DB >> 17172650

Following the TRAIL to apoptosis.

Bharti R Chaudhari1, Richard F Murphy, Devendra K Agrawal.   

Abstract

Apoptosis, programmed cell death, eliminates injured or harmful cells. It can mediate its response through the actions of death ligands including TRAIL. TRAIL, a member of TNF superfamily, induces apoptosis of transformed cells through the action of death domain receptors DR-4 and DR5. It directly induces apoptosis through an extrinsic pathway, which involves the activation of caspases. TRAIL also is able to prevent apoptosis through the actions of its decoy receptors DcR-1 and DcR-2. Various regulators of TRAIL include FADD, IAPs, Bcl-2s, p53, and FLIPs. TRAIL is present in cells involved in asthma including eosinophils, mast cells, fibroblasts, and airway epithelial cells. It is expressed in airway remodeling and may be linked with the pathways of transforming growth factor-beta1, which is thought to cause damage to the epithelium. The repair process of the epithelium is hindered as a result of increased apoptosis induced by TGF-beta1, which overlaps with the pathways of TRAIL. Analogs of TRAIL could have therapeutical applications for asthma. TRAIL is also seen as the basis for a "miracle" drug for cancer because of its ability to selectively kill cancer cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17172650     DOI: 10.1385/IR:35:3:249

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  80 in total

Review 1.  Myofibroblasts and mechano-regulation of connective tissue remodelling.

Authors:  James J Tomasek; Giulio Gabbiani; Boris Hinz; Christine Chaponnier; Robert A Brown
Journal:  Nat Rev Mol Cell Biol       Date:  2002-05       Impact factor: 94.444

2.  Differential expression of TRAIL and TRAIL receptors in allergic asthmatics following segmental antigen challenge: evidence for a role of TRAIL in eosinophil survival.

Authors:  Noreen M Robertson; James G Zangrilli; Andrzej Steplewski; Annette Hastie; Rochelle G Lindemeyer; Maria A Planeta; Mary K Smith; Nathalie Innocent; Ali Musani; Rodolfo Pascual; Stephen Peters; Gerald Litwack
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

3.  The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways.

Authors:  T Kataoka; R C Budd; N Holler; M Thome; F Martinon; M Irmler; K Burns; M Hahne; N Kennedy; M Kovacsovics; J Tschopp
Journal:  Curr Biol       Date:  2000-06-01       Impact factor: 10.834

4.  Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex.

Authors:  A Krueger; I Schmitz; S Baumann; P H Krammer; S Kirchhoff
Journal:  J Biol Chem       Date:  2001-03-05       Impact factor: 5.157

5.  TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.

Authors:  C S Mitsiades; S P Treon; N Mitsiades; Y Shima; P Richardson; R Schlossman; T Hideshima; K C Anderson
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

6.  Inhibition of death receptor signals by cellular FLIP.

Authors:  M Irmler; M Thome; M Hahne; P Schneider; K Hofmann; V Steiner; J L Bodmer; M Schröter; K Burns; C Mattmann; D Rimoldi; L E French; J Tschopp
Journal:  Nature       Date:  1997-07-10       Impact factor: 49.962

7.  Tumor necrosis factor-related apoptosis-inducing ligand alters mitochondrial membrane lipids.

Authors:  Ferry Sandra; Mauro Degli Esposti; Kenneth Ndebele; Philimon Gona; David Knight; Magnus Rosenquist; Roya Khosravi-Far
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

8.  Apoptosis induced by TGF-beta 1 in Burkitt's lymphoma cells is caspase 8 dependent but is death receptor independent.

Authors:  G J Inman; M J Allday
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

9.  Transforming growth factor-beta1 promoter polymorphism C-509T is associated with asthma.

Authors:  Eric S Silverman; Lyle J Palmer; Venkat Subramaniam; Arlene Hallock; Sheeba Mathew; Joseph Vallone; Debora S Faffe; Toshiki Shikanai; Benjamin A Raby; Scott T Weiss; Stephanie A Shore
Journal:  Am J Respir Crit Care Med       Date:  2003-11-03       Impact factor: 21.405

10.  CD28-dependent activation of protein kinase B/Akt blocks Fas-mediated apoptosis by preventing death-inducing signaling complex assembly.

Authors:  Russell G Jones; Alisha R Elford; Michael J Parsons; Linda Wu; Connie M Krawczyk; Wen-Chen Yeh; Razqallah Hakem; Robert Rottapel; James R Woodgett; Pamela S Ohashi
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307

View more
  12 in total

1.  RIPK1 and CASP7 polymorphism as prognostic markers for survival in patients with colorectal cancer after complete resection.

Authors:  Yee Soo Chae; Jong Gwang Kim; Sang Kyun Sohn; Su Jeong Lee; Byung Woog Kang; Joon Ho Moon; Jae Yong Park; Seong Woo Jeon; Han-Ik Bae; Gyu Seog Choi; Soo-Han Jun
Journal:  J Cancer Res Clin Oncol       Date:  2010-06-22       Impact factor: 4.553

2.  Increased expression of inhibitor of apoptosis proteins in atherosclerotic plaques of symptomatic patients with carotid stenosis.

Authors:  Edward P Moran; Devendra K Agrawal
Journal:  Exp Mol Pathol       Date:  2007-01-17       Impact factor: 3.362

3.  The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases.

Authors:  Brett D Shepard; Andrew D Badley
Journal:  Antiinfect Agents Med Chem       Date:  2009-04-01

4.  Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells.

Authors:  Imtiyaz Murtaza; Mohammad Saleem; Vaqar Mustafa Adhami; Bilal Bin Hafeez; Hasan Mukhtar
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 5.  Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy.

Authors:  Ahmad R Safa; Travis W Day; Ching-Huang Wu
Journal:  Curr Cancer Drug Targets       Date:  2008-02       Impact factor: 3.428

Review 6.  Corticosteroids for multiple sclerosis: I. Application for treating exacerbations.

Authors:  Elliot M Frohman; Anjali Shah; Eric Eggenberger; Luanne Metz; Robert Zivadinov; Olaf Stüve
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

7.  TNF superfamily gene polymorphism as prognostic factor in early breast cancer.

Authors:  Jin Hyang Jung; Yee Soo Chae; Joon Ho Moon; Byung Woog Kang; Jong Gwang Kim; Sang Kyun Sohn; Ji Young Park; Myung Hoon Lee; Ho Yong Park
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-05       Impact factor: 4.553

8.  Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region.

Authors:  Karthikeyan Kandasamy; Andrew S Kraft
Journal:  Mol Cancer Ther       Date:  2008-05       Impact factor: 6.261

9.  Soluble trail as a marker of efficacy of allergen-specific immunotherapy in patients with allergic rhinoconjunctivitis.

Authors:  Arzu Didem Yalcin; Saadet Gumuslu; Gizem Esra Parlak; Atil Bısgın
Journal:  Med Sci Monit       Date:  2012-10

10.  The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling.

Authors:  Kristine A Drafahl; Christopher W McAndrew; April N Meyer; Martin Haas; Daniel J Donoghue
Journal:  PLoS One       Date:  2010-12-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.